episode 834: COVID-19 clinical update #90 with Dr. Daniel Griffin
In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Expanded eligibility for booster doses (FDA)
- More rapid antigen tests approved (FDA)
- Immune correlates for mRNA-1273 (Science)
- Risk for still birth with and without COVID-19 (MMWR)
- PROVENT phase III prophylaxis trial (AstraZenica)
- Fluvoxamine guidelines (IDSA)
- COVID-OUT trial (Univ Minnesota)
- Monoclonal antibody treatment in vaccinated infected (J Inf Dis)
- Steroid use in non-oxygen requiring patients (QJM)
- Doxycycline trial (Lancet)
- Efficacy of inhaled ciclesonide (JAMA)
- Advise on use of molnupiravir (EMA)
- Text messaging for monitoring disease (Ann Int Med)
- Long COVID after vaccination and infection (Res Square)
- Ivermectin for West Nile virus (Medpage Today)
- Letters read on TWiV 834
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv